Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Glioblastoma is an incurable brain cancer characterized by high genetic and pathological heterogeneity. Here, we mapped active chromatin landscapes with gene expression, whole exomes, copy number profiles, and DNA methylomes across 44 patient-derived glioblastoma stem cells (GSCs), 50 primary tumors, and 10 neural stem cells (NSCs) to identify essential super-enhancer (SE)–associated genes and the core transcription factors that establish SEs and maintain GSC identity. GSCs segregate into two groups dominated by distinct enhancer profiles and unique developmental core transcription factor regulatory programs. Group-specific transcription factors enforce GSC identity; they exhibit higher activity in glioblastomas versus NSCs, are associated with poor clinical outcomes, and are required for glioblastoma growth in vivo. Although transcription factors are commonly considered undruggable, group-specific enhancer regulation of the MAPK/ERK pathway predicts sensitivity to MEK inhibition. These data demonstrate that transcriptional identity can be leveraged to identify novel dependencies and therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 6×
“…clinical outcome, we derived a gene signature composed of the top 250 SE-regulated genes identified in GSCs, which predicted patient survival in an independent set of transcriptional profiles defined by The Cancer Genome Atlas (TCGA; Verhaak et al., 2010; Brennan et al., 2013; Wang et al., 2018a).”
BackgroundMethodResultInfluentialVan der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687 · cited 1×
“…3.8 in accordance with the Genome Analysis Toolkit best practices with the principal steps of base quality score recalibration, variant genotyping for singlenucleotide variants and indels, and variant hard-filtering with standard recommendations (DePristo et al., 2011; Van der Auwera et al., 2013).”
MethodInfluentialIntegrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Although GBM has been extensively characterized at the molecular level, current clinical management has limited guidance from molecular pathology, beyond mutations in isocitrate dehydrogenase 1/2 (IDH1/2) and MGMT promoter methylation (Hegi et al., 2005; Cancer Genome Atlas Research Network, 2008; Parsons et al., 2008…”
BackgroundIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 4×
“Additionally, gliomas have high intratumoral phenotypic heterogeneity, leading to the hypothesis that self-renewing GBM stem cells (GSCs) persist after therapy and are able to regenerate refractory tumors (Singh et al., 2004; Bao et al., 2006; Chen et al., 2012a; Patel et al., 2014; Suvà et al., 2014).”
BackgroundMethodInfluentialThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Self-citationFIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247 · cited 1×
“Group-specific TF core regulatory circuitries are recapitulated in primary tumors Primary GBMs exhibit high intratumoral heterogeneity and are highly dynamic to signaling queues from the tumor microenvironment (Hu et al., 2016; Venkatesh et al., 2017; Griveau et al., 2018; Wang et al., 2018b).”
Cited by
Dixit, D., Prager, B. C., Gimple, R. C., Poh, H. X., Wang, Y., Wu, Q., Qiu, Z., Kidwell, R. L., Kim, L. J. Y., Xie, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0331 · Cited by 410
Self-citationGlioblastoma Stem Cells: Driving Resilience through Chaos
Prager, B. C., Bhargava, S., Mahadev, V., Hubert, C. G., & Rich, J. N. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.009 · Cited by 401
Self-citationFunctional Enhancers Shape Extrachromosomal Oncogene Amplifications
Morton, A. R., Dogan-Artun, N., Faber, Z. J., MacLeod, G., Bartels, C. F., Piazza, M. S., Allan, K. C., Mack, S. C., Wang, X., Gimple, R. C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.039 · Cited by 343
Self-citationTang, M., Xie, Q., Gimple, R. C., Zhong, Z., Tam, T., Tian, J., Kidwell, R. L., Wu, Q., Prager, B. C., Qiu, Z., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0338-1 · Cited by 290
Self-citationFBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells
Shen, J. Z., Qiu, Z., Wu, Q., Finlay, D., Garcia, G., Sun, D., Rantala, J., Barshop, W., Hope, J. L., Gimple, R. C., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.042 · Cited by 113
Self-citationGlioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype
Wu, Y., Fletcher, M., Gu, Z., Wang, Q., Costa, B., Bertoni, A., Man, K.-H., Schlotter, M., Felsberg, J., Mangei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20225-w · Cited by 101
A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia
(2022) · doi:10.1101/gad.349284.121 · Cited by 31
Metadata
- Authors
- Mack, S. C., Singh, I., Wang, X., Hirsch, R., Wu, Q., Villagomez, R., Bernatchez, J. A., Zhu, Z., Gimple, R. C., Kim, L. J. Y., Morton, A., Lai, S., Qiu, Z., Prager, B. C., Bertrand, K. C., Mah, C., Zhou, W., Lee, C., Barnett, G. H., Vogelbaum, M. A., Sloan, A. E., Chavez, L., Bao, S., Scacheri, P. C., Siqueira-Neto, J. L., Lin, C. Y., & Rich, J. N.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2019-04-04
- Volume
- 216
- Issue
- 5
- Pages
- 1071-1090
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2927602615
- Cited by
- 130
- References
- 24
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.